vs

Side-by-side financial comparison of Tarsus Pharmaceuticals, Inc. (TARS) and WW INTERNATIONAL, INC. (WW). Click either name above to swap in a different company.

WW INTERNATIONAL, INC. is the larger business by last-quarter revenue ($184.3M vs $151.7M, roughly 1.2× Tarsus Pharmaceuticals, Inc.). Tarsus Pharmaceuticals, Inc. runs the higher net margin — -5.5% vs -30.5%, a 25.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -4.5%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $8.4M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -7.4%).

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

WW International, Inc., formerly Weight Watchers International, Inc., is a global company headquartered in the U.S. that offers weight loss and maintenance, fitness, and mindset services such as the Weight Watchers comprehensive diet program. Founded in 1963 by Queens, New York City homemaker Jean Nidetch, WW's program has three options as of 2019: online via its mobile app and website, coaching online or by phone, or in-person meetings.

TARS vs WW — Head-to-Head

Bigger by revenue
WW
WW
1.2× larger
WW
$184.3M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+132.9% gap
TARS
128.4%
-4.5%
WW
Higher net margin
TARS
TARS
25.0% more per $
TARS
-5.5%
-30.5%
WW
More free cash flow
TARS
TARS
$4.6M more FCF
TARS
$13.0M
$8.4M
WW
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-7.4%
WW

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
TARS
TARS
WW
WW
Revenue
$151.7M
$184.3M
Net Profit
$-8.4M
$-56.3M
Gross Margin
72.2%
Operating Margin
-5.3%
5.8%
Net Margin
-5.5%
-30.5%
Revenue YoY
128.4%
-4.5%
Net Profit YoY
63.8%
-21.8%
EPS (diluted)
$-0.17
$-5.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TARS
TARS
WW
WW
Q4 25
$151.7M
Q3 25
$118.7M
$184.3M
Q2 25
$102.7M
Q1 25
$78.3M
$186.6M
Q4 24
$66.4M
$184.4M
Q3 24
$48.1M
$192.9M
Q2 24
$40.8M
$202.1M
Q1 24
$27.6M
$206.5M
Net Profit
TARS
TARS
WW
WW
Q4 25
$-8.4M
Q3 25
$-12.6M
$-56.3M
Q2 25
$-20.3M
Q1 25
$-25.1M
$-72.6M
Q4 24
$-23.1M
$25.1M
Q3 24
$-23.4M
$-46.2M
Q2 24
$-33.3M
$23.3M
Q1 24
$-35.7M
$-347.9M
Gross Margin
TARS
TARS
WW
WW
Q4 25
Q3 25
72.2%
Q2 25
Q1 25
71.2%
Q4 24
69.7%
Q3 24
67.1%
Q2 24
67.9%
Q1 24
66.7%
Operating Margin
TARS
TARS
WW
WW
Q4 25
-5.3%
Q3 25
-12.2%
5.8%
Q2 25
-21.6%
Q1 25
-33.5%
-10.8%
Q4 24
-36.8%
19.6%
Q3 24
-52.3%
-20.2%
Q2 24
-81.6%
17.8%
Q1 24
-136.5%
-130.4%
Net Margin
TARS
TARS
WW
WW
Q4 25
-5.5%
Q3 25
-10.6%
-30.5%
Q2 25
-19.8%
Q1 25
-32.1%
-38.9%
Q4 24
-34.8%
13.6%
Q3 24
-48.7%
-23.9%
Q2 24
-81.6%
11.5%
Q1 24
-129.4%
-168.4%
EPS (diluted)
TARS
TARS
WW
WW
Q4 25
$-0.17
Q3 25
$-0.30
$-5.63
Q2 25
$-0.48
Q1 25
$-0.64
$-0.91
Q4 24
$-0.57
$0.34
Q3 24
$-0.61
$-0.58
Q2 24
$-0.88
$0.29
Q1 24
$-1.01
$-4.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TARS
TARS
WW
WW
Cash + ST InvestmentsLiquidity on hand
$417.3M
$170.1M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$343.4M
$323.0M
Total Assets
$562.2M
$968.8M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TARS
TARS
WW
WW
Q4 25
$417.3M
Q3 25
$401.8M
$170.1M
Q2 25
$381.1M
Q1 25
$407.9M
$236.3M
Q4 24
$291.4M
$53.0M
Q3 24
$317.0M
$57.2M
Q2 24
$323.6M
$42.7M
Q1 24
$298.5M
$66.6M
Total Debt
TARS
TARS
WW
WW
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
$1.4B
Q3 24
$71.7M
$1.4B
Q2 24
$71.6M
$1.4B
Q1 24
$29.9M
$1.4B
Stockholders' Equity
TARS
TARS
WW
WW
Q4 25
$343.4M
Q3 25
$335.1M
$323.0M
Q2 25
$332.6M
Q1 25
$342.5M
$-1.2B
Q4 24
$224.5M
$-1.1B
Q3 24
$237.5M
$-1.1B
Q2 24
$252.2M
$-1.1B
Q1 24
$275.2M
$-1.1B
Total Assets
TARS
TARS
WW
WW
Q4 25
$562.2M
Q3 25
$534.6M
$968.8M
Q2 25
$495.0M
Q1 25
$500.8M
$696.9M
Q4 24
$377.0M
$550.3M
Q3 24
$376.3M
$562.4M
Q2 24
$376.8M
$614.3M
Q1 24
$349.3M
$654.2M
Debt / Equity
TARS
TARS
WW
WW
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TARS
TARS
WW
WW
Operating Cash FlowLast quarter
$19.3M
$8.4M
Free Cash FlowOCF − Capex
$13.0M
$8.4M
FCF MarginFCF / Revenue
8.6%
4.6%
Capex IntensityCapex / Revenue
4.2%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M
$44.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TARS
TARS
WW
WW
Q4 25
$19.3M
Q3 25
$18.3M
$8.4M
Q2 25
$-29.4M
Q1 25
$-20.7M
$15.0M
Q4 24
$-22.2M
$4.6M
Q3 24
$-8.7M
$16.5M
Q2 24
$-14.4M
$-1.9M
Q1 24
$-37.8M
$-36.0M
Free Cash Flow
TARS
TARS
WW
WW
Q4 25
$13.0M
Q3 25
$16.3M
$8.4M
Q2 25
$-30.4M
Q1 25
$-21.2M
$15.0M
Q4 24
$-22.3M
$4.5M
Q3 24
$-8.9M
$16.4M
Q2 24
$-15.4M
$-2.2M
Q1 24
$-38.0M
$-36.5M
FCF Margin
TARS
TARS
WW
WW
Q4 25
8.6%
Q3 25
13.8%
4.6%
Q2 25
-29.6%
Q1 25
-27.1%
8.0%
Q4 24
-33.5%
2.4%
Q3 24
-18.6%
8.5%
Q2 24
-37.8%
-1.1%
Q1 24
-137.5%
-17.7%
Capex Intensity
TARS
TARS
WW
WW
Q4 25
4.2%
Q3 25
1.6%
0.0%
Q2 25
1.0%
Q1 25
0.8%
0.0%
Q4 24
0.1%
0.1%
Q3 24
0.6%
0.1%
Q2 24
2.5%
0.1%
Q1 24
0.6%
0.2%
Cash Conversion
TARS
TARS
WW
WW
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.18×
Q3 24
Q2 24
-0.08×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons